Pacritinib (SB1518)

Pacritinib (SB1518) is an inhibitor of FLT3 and JAK2 used in studies of MAPK / ERK Signaling and JAK-STAT Signaling. In practice, this places the compound in experiments that measure mitogenic kinase cascades, proliferation control, and differentiation-linked signaling and cytokine-responsive transcriptional signaling and immune regulation in cancer, cell signaling, and immunology models.

By inhibiting FLT3 and JAK2, Pacritinib (SB1518) can be used to examine mitogenic kinase cascades, proliferation control, and differentiation-linked signaling and cytokine-responsive transcriptional signaling and immune regulation. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In cancer, cell signaling, and immunology models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving FLT3 and JAK2
• Pathway perturbation studies connected to MAPK / ERK Signaling and JAK-STAT Signaling
• Concentration-response inhibition and target-dependence studies
• Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, Pacritinib (SB1518) is appropriate when a defined chemical perturbant is needed to connect FLT3 and JAK2 with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in cancer, cell signaling, and immunology models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.